Shares of Akeso (09926) are now up more than 3%, up 3.08% to HKD 40.15 as of press time, with a turnover of 40.7542 million Hong Kong dollars.
The Smart Finance app has learned that shares of Akeso (09926) are now up more than 3%, up 3.08% to HKD 40.15 as of press time, with a turnover of 40.7542 million Hong Kong dollars.
Debon Securities pointed out that AK112 is expected to be approved for listing in May 2024 and used to treat locally advanced or metastatic nsqNSCLC progresses with EGFR-TKI, and the total review time is less than 10 months, exceeding expectations. The data from the head-to-head study with K drug enhances the commercial prospect and the certainty of overseas success of AK112 significantly. The bank has raised its domestic peak sales forecast by CNY 6 billion and the overseas peak value by USD 3 billion.
The bank pointed out that at the same time, PCSK9 and IL12/23 products have been accepted for NDA in 2023, and IL17 will proceed with the new drug marketing application (NDA) after obtaining safety data for the entire research period. IL4R, as a potential product, is in the registered clinical stage, and the international clinical trial of CD47 is in Phase II. In terms of innovative research and development, the company has multiple ADC pipelines under research, and the layout of IO+ADC in the future is more promising. The certainty of AK112's successful overseas launch is gradually increasing, and the overseas value is not fully recognized. We believe that the company has the potential to evolve into a first-class Chinese biopharmaceutical company with international competitiveness, and its current market cap is severely underestimated.